Literature DB >> 8055930

A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease.

J Freund1, R Kellner, J Konvalinka, V Wolber, H G Kräusslich, H R Kalbitzer.   

Abstract

Negative factor (Nef) protein from human immunodeficiency virus type 1 (HIV-1) is cleaved into two well-defined domains by the HIV-1-encoded protease. The cleavage site is located between Trp57 and Leu58 and is well conserved. The two domains are stable in the presence of protease for more than 48 h. The C-terminal core domain contains a well-conserved well-folded region. The cleavage releases the core domain from the myristoylated membrane anchor domain. As is the case for other HIV proteins, cleavage of Nef could be crucial for correct biological function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8055930     DOI: 10.1111/j.1432-1033.1994.tb19029.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  21 in total

1.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.

Authors:  E Schaeffer; R Geleziunas; W C Greene
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

Review 3.  Structure--function relationships in HIV-1 Nef.

Authors:  M Geyer; O T Fackler; B M Peterlin
Journal:  EMBO Rep       Date:  2001-07       Impact factor: 8.807

4.  Pol-specific CD8+ T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation.

Authors:  Jonah B Sacha; Chungwon Chung; Jason Reed; Anna K Jonas; Alexander T Bean; Sean P Spencer; Wonhee Lee; Lara Vojnov; Richard Rudersdorf; Thomas C Friedrich; Nancy A Wilson; Jeffrey D Lifson; David I Watkins
Journal:  J Virol       Date:  2007-08-15       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Specific cleavage sites of Nef proteins from human immunodeficiency virus types 1 and 2 for the viral proteases.

Authors:  J Schorr; R Kellner; O Fackler; J Freund; J Konvalinka; N Kienzle; H G Kräusslich; N Mueller-Lantzsch; H R Kalbitzer
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

Review 7.  Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.

Authors:  K Ikuta; S Suzuki; H Horikoshi; T Mukai; R B Luftig
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

8.  Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.

Authors:  Mina Henes; Klajdi Kosovrasti; Gordon J Lockbaum; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer; Troy W Whitfield
Journal:  Biochemistry       Date:  2019-08-19       Impact factor: 3.162

9.  Alkylating HIV-1 Nef - a potential way of HIV intervention.

Authors:  Yong-Jiu Jin; Xiaoping Zhang; Catherine Yi Cai; Steven J Burakoff
Journal:  AIDS Res Ther       Date:  2010-07-26       Impact factor: 2.250

10.  Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Authors:  Michael F Maguire; Rosario Guinea; Philip Griffin; Sarah Macmanus; Robert C Elston; Josie Wolfram; Naomi Richards; Mary H Hanlon; David J T Porter; Terri Wrin; Neil Parkin; Margaret Tisdale; Eric Furfine; Chris Petropoulos; B Wendy Snowden; Jörg-Peter Kleim
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.